Table 2. Drugs used and their IC50 values (μM) in MPM cells.
| Drugs | Drug targets | H2052 | H2452 | H28 | MSTO-211H |
|---|---|---|---|---|---|
| Carboplatin | DNA | 5.30±1.02 | 2.69±0.71 | 10.50±2.59 | 0.51±0.12 |
| Pemetrexed | TS, DHFR, GARFT | 0.07±0.01 | 2.82±0.17 | 10.96±2.46 | 0.02±0.01 |
| Vandetanib | EGFR, VEGFR-2/3, RET | 1.07±0.04 | 3.52±1.13 | 0.32±0.07 | 1.42±0.03 |
| Sorafenib | Raf, PDGF, VEGFR-2/3 | 6.09±1.78 | 14.59±4.58 | 10.22±1.93 | 3.18±0.27 |
| Gefitinib | EGFR | 5.22±1.53 | 4.83±1.24 | 3.99±1.28 | 4.91±1.04 |
| Erlotinib | EGFR | 5.55±1.28 | 5.26±1.29 | 3.92±1.06 | 5.48±1.93 |
| Enzastaurin | PKCβ, VEGF | 11.56±3.82 | 10.07±2.96 | 8.11±2.19 | 10.92±2.59 |
| ZM447439 | Aurora kinase B | 12.73±3.49 | 10.40±3.27 | 11.12±4.02 | 9.65±3.06 |
Abbreviations: DHFR=dihydrofolate reductase; DMSO=dimethyl sulfoxide; EGFR=epidermal growth factor receptor; GARFT=glycinamide ribonucleotide formyltransferase; MTT=3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PDGF=platelet-derived growth factor; PKCβ=protein kinase Cβ; RET=rearranged during transfection; SRB=sulforhodamine B; TS=thymidylate synthase; VEGFR=vascular endothelial growth factor receptor; MPM=malignant pleural mesothelioma.
Notes: The drugs were dissolved in DMSO or sterile water and diluted in culture medium before use. IC50 concentrations were calculated as mean values±s.e.m. of at least three independent MTT or SRB experiments.